Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) – Pipeline Review, H1 2017’, provides in depth analysis on Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology and Cardiovascular under development targeting Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)

The report reviews Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Astellas Pharma Inc

BerGenBio ASA

Betta Pharmaceuticals Co Ltd

Celldex Therapeutics Inc

Exelixis Inc

Ignyta Inc

Les Laboratoires Servier SAS

Mirati Therapeutics Inc

Ono Pharmaceutical Co Ltd

Oribase Pharma

Qurient Co Ltd

SignalChem Lifesciences Corp

Takeda Pharmaceutical Company Ltd

Tolero Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Overview

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Companies Involved in Therapeutics Development

Astellas Pharma Inc

BerGenBio ASA

Betta Pharmaceuticals Co Ltd

Celldex Therapeutics Inc

Exelixis Inc

Ignyta Inc

Les Laboratoires Servier SAS

Mirati Therapeutics Inc

Ono Pharmaceutical Co Ltd

Oribase Pharma

Qurient Co Ltd

SignalChem Lifesciences Corp

Takeda Pharmaceutical Company Ltd

Tolero Pharmaceuticals Inc

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Drug Profiles

Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-324 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-9016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cabozantinib s-malate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-053 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-413 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gilteritinib fumarate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glesatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HOPE-777 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody 3 to Inhibit AXL Kinase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugate to Inhibit AXL Kinase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-7475 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Q-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit Axl Tyrosine kinase for Thrombosis and Non-Small Cell Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXDX-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-49076 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGI-7079 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sitravatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLC-0211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit AXL for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit AXL, FLT3 and ARK5 for Solid Tumor and Hematological Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit AXL, FLT3 and NTRK for Solid Tumors and Blood Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-0903 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Dormant Products

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Discontinued Products

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Product Development Milestones

Featured News & Press Releases

May 22, 2017: BerGenBio Announces Start of Randomized Phase I/II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with Current Therapies in Melanoma

May 19, 2017: Abstract showing activity in MDS of BerGenBio’s first-in-class AXL inhibitor, BGB324, accepted for presentation at ASCO Annual Meeting 2017

Apr 04, 2017: Ignyta Announces New Data Highlighting Broad Potential of RXDX-106 at the 2017 AACR Annual Meeting

Mar 28, 2017: Ignyta Announces Multiple Presentations at the 2017 AACR Annual Meeting

Mar 06, 2017: Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma

Feb 17, 2017: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Jan 09, 2017: BerGenBio To Present At 9th Annual Biotech Showcase 2017

Jan 05, 2017: Mirati Therapeutics Provides Update On Glesatinib Clinical Trial And Pipeline Program

Jan 05, 2017: Mirati Therapeutics Provides Update On Sitravatinib Clinical Trial And Pipeline Program

Dec 08, 2016: New Breast Cancer Research Highlights BGB324 In Overcoming Immunotherapy Resistance

Dec 07, 2016: Exelixis Announces Leadership Hires in Public Affairs and Business Development to Support Growth of Company and Pipeline

Dec 05, 2016: BerGenBio Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML at ASH 2016

Nov 29, 2016: BerGenBio Reports Promising BGB324 Phase I/II Monotherapy Data in Patients with Lung Cancer at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

Nov 29, 2016: Ignyta to Debut Preclinical Data on RXDX-106 at the 2016 EORTC-NCI-AACR Annual Meeting

Nov 17, 2016: Astellas Oncology Announces New Data in Acute Myeloid Leukemia to be Presented at the 2016 ASH Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Astellas Pharma Inc, H1 2017

Pipeline by BerGenBio ASA, H1 2017

Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017

Pipeline by Celldex Therapeutics Inc, H1 2017

ipeline by Exelixis Inc, H1 2017

Pipeline by Ignyta Inc, H1 2017

Pipeline by Les Laboratoires Servier SAS, H1 2017

Pipeline by Mirati Therapeutics Inc, H1 2017

Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Pipeline by Oribase Pharma, H1 2017

Pipeline by Qurient Co Ltd, H1 2017

Pipeline by SignalChem Lifesciences Corp, H1 2017

Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Pipeline by Tolero Pharmaceuticals Inc, H1 2017

Dormant Products, H1 2017

Dormant Products, H1 2017 (Contd..1), H1 2017

Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports